StockData
Apimeds Pharmaceuticals US, Inc. logo

Apimeds Pharmaceuticals US, Inc. (APUS) stock

APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30
$1.95−0.09 (-4.41%)

Close on Nov 17, 2026Market cap $2.94MP/E –Yield –

Apimeds Pharmaceuticals US operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Apimeds Pharmaceuticals US's operating cash flow for the twelve months ending Jun 30, 2026 was -$13.28M. For fiscal 2025 it was -$8.93M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.93M–
FY2024Dec 31, 2024-$733.53K–
FY2023Dec 31, 2023-$627.79K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.67M–
Q1 FY2026Mar 31, 2026-$2.07M–
Q4 FY2025Dec 31, 2025-$3.82M–
Q3 FY2025Sep 30, 2025-$1.73M–
Q2 FY2025Jun 30, 2025-$3.36M–
Q1 FY2025Mar 31, 2025-$20.31K–
Q4 FY2024Dec 31, 2024-$99.62K–
Q3 FY2024Sep 30, 2024-$186.76K–
Q2 FY2024Jun 30, 2024-$184.06K–
Q1 FY2024Mar 31, 2024-$263.10K–

More Apimeds Pharmaceuticals US figures

See a number that looks wrong?